Complete Remission of Advanced Hepatocellular Carcinoma in a Patient With Ulcerative Colitis Treated With Atezolizumab and Bevacizumab: A Case Report
Related Experiment Video
Updated: Jul 25, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Swetha Pentapati1, Stephen Caucci2, Shravya Balmuri3
1Hematology and Oncology, Michigan State University College of Human Medicine, Lansing, USA.
Abstract:
In this case study, a 73-year-old man who had previously undergone colectomy had a history of ulcerative colitis and alcohol abuse and presented with fatigue, weight loss, and a liver lesion. After a biopsy, he was diagnosed with stage IV-A hepatocellular carcinoma with poor differentiation and cirrhotic architecture, and molecular testing revealed positivity for multiple genes. A combination of atezolizumab and bevacizumab was administered, resulting in complete remission lasting beyond 16 months, demonstrating the potential of these drugs as a treatment option for advanced hepatocellular carcinoma (HCC). The patient's history of autoimmune conditions could have contributed to his robust response to the treatment. The report highlights the sustained survival benefits of this treatment beyond month 16.
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Treatment Resistant Cancers
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Tumor Immunotherapy
Chronic Pancreatitis II: Collaborative Care
Assessment:
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

